Jazz Pharmaceuticals PLC JAZZ
We take great care to ensure that the data presented and summarized in this overview for Jazz Pharmaceuticals plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding JAZZ
View all-
Black Rock Inc. New York, NY6.15MShares$873 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.04MShares$858 Million0.01% of portfolio
-
Lsv Asset Management Chicago, IL2.53MShares$360 Million0.72% of portfolio
-
Pacer Advisors, Inc. Malvern, PA2.21MShares$315 Million0.67% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.04MShares$289 Million0.06% of portfolio
-
State Street Corp Boston, MA1.97MShares$280 Million0.01% of portfolio
-
Capital World Investors Los Angeles, CA1.92MShares$273 Million0.04% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN1.83MShares$260 Million0.06% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA1.71MShares$242 Million9.82% of portfolio
-
Jpmorgan Chase & CO New York, NY1.59MShares$226 Million0.02% of portfolio
Latest Institutional Activity in JAZZ
Top Purchases
Top Sells
About JAZZ
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
Insider Transactions at JAZZ
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 10
2025
|
Robert Iannone EVP, Global Head of R&D & CMO |
SELL
Open market or private sale
|
Direct |
2,403
-2.93%
|
$331,614
$138.41 P/Share
|
Mar 10
2025
|
Patricia Carr SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,140
-13.98%
|
$156,180
$137.81 P/Share
|
Mar 07
2025
|
Patricia Carr SVP, Chief Accounting Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,333
-14.05%
|
$183,954
$138.23 P/Share
|
Mar 07
2025
|
Mary Elizabeth Henderson SVP, Technical Operations |
SELL
Sale (or disposition) back to the issuer
|
Direct |
698
-2.94%
|
$96,324
$138.23 P/Share
|
Mar 07
2025
|
Robert Iannone EVP, Global Head of R&D & CMO |
SELL
Open market or private sale
|
Direct |
7,080
-4.03%
|
$984,120
$139.11 P/Share
|
Mar 05
2025
|
Samantha Pearce EVP, Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,905
-4.42%
|
$262,890
$138.95 P/Share
|
Mar 05
2025
|
Neena M Patil EVP & Chief Legal Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,088
-7.92%
|
$564,144
$138.95 P/Share
|
Mar 05
2025
|
Philip L Johnson EVP & Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,149
-2.24%
|
$158,562
$138.95 P/Share
|
Mar 05
2025
|
Renee D Gala President & COO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,704
-6.03%
|
$787,152
$138.95 P/Share
|
Mar 05
2025
|
Robert Iannone EVP, Global Head of R&D & CMO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,239
-5.55%
|
$722,982
$138.95 P/Share
|
Mar 05
2025
|
Bruce C Cozadd Chairman & CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
22,251
-4.79%
|
$3,070,638
$138.95 P/Share
|
Mar 03
2025
|
Bruce C Cozadd Chairman & CEO |
SELL
Open market or private sale
|
Direct |
6,500
-1.38%
|
$936,000
$144.25 P/Share
|
Feb 28
2025
|
Patricia Carr SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
773
-7.54%
|
$110,539
$143.29 P/Share
|
Feb 27
2025
|
Robert Iannone EVP, Global Head of R&D & CMO |
BUY
Grant, award, or other acquisition
|
Direct |
26,577
+12.88%
|
-
|
Feb 27
2025
|
Mary Elizabeth Henderson SVP, Technical Operations |
BUY
Grant, award, or other acquisition
|
Direct |
9,244
+17.62%
|
-
|
Feb 27
2025
|
Samantha Pearce EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,719
+18.02%
|
-
|
Feb 27
2025
|
Renee D Gala President & COO |
BUY
Grant, award, or other acquisition
|
Direct |
34,666
+16.33%
|
-
|
Feb 27
2025
|
Patricia Carr SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,889
+21.97%
|
-
|
Feb 27
2025
|
Patricia Carr SVP, Chief Accounting Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
868
-5.41%
|
$123,256
$142.43 P/Share
|
Feb 27
2025
|
Patricia Carr SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
4,813
-19.5%
|
$693,072
$144.42 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 266K shares |
---|---|
Exercise of conversion of derivative security | 4.81K shares |
Payment of exercise price or tax liability | 34.9K shares |
---|---|
Sale (or disposition) back to the issuer | 43.2K shares |
Open market or private sale | 42.8K shares |